Soleno Therapeutics is a healthcare company focused on developing innovative therapies for rare diseases. Its core product is a treatment for Prader-Willi syndrome, a genetic disorder that leads to severe obesity and other health issues. The company operates primarily in the biopharmaceutical segment, with its main revenue source derived from product sales and potential future royalties. Soleno is engaged in clinical trials to expand its product offerings and address unmet medical needs.
The investment profile of Soleno Therapeutics is more aligned with growth investors, given its focus on developing new therapies and potential market expansion. The company does not currently offer dividends, making it less suitable for income-focused investors. The stock may appeal to those looking for long-term capital appreciation as it navigates clinical developments and market entry.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-09 02:51 | Hold | Buy | Positive momentum but mixed fundamentals and analyst signals. |
| 2026-05-24 02:50 | Buy | Hold | Mixed performance with moderate risk; hold for now. |
| 2026-05-08 15:31 | — | Buy | Strong growth, but uncertain market signals. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-04-17 09:17 | Wells Fargo | Rating Downgraded | — → 53 | 52.57 |
| 2026-03-04 11:41 | H.C. Wainwright | Target Lowered | — → 100 | 38.495 |
| 2026-01-20 11:19 | Wells Fargo | Target Raised | 106 → 114 | 42.48 |
